Therapy using antibodies against PDL1 have shown significant improvement experimentally as well as in clinical studies to restore the cytotoxic attack of T-lymphocytes towards tumor cells in several solid malignancies[3,6,10]. The gene discussed is CD274; the disease is neoplasm.